Oragenics Inc. (OGEN)
Oragenics Inc. (OGEN) is a biotechnology company focused on developing innovative vaccines and antibiotics to combat infectious diseases. The company primarily works on probiotics and therapeutic products to address bacterial infections and enhance immune responses, aiming to improve public health outcomes through novel microbial-based solutions.
Company News
Oragenics, Inc. has submitted a clinical trial protocol for regulatory review to the Health and Disability Ethics Committee in New Zealand for its Phase II trial evaluating ONP-002, a proprietary neurosteroid therapy, for the treatment of mild traumatic brain injury or concussion.
Oragenics, a biopharmaceutical company, has postponed its 2023 Annual Meeting of Shareholders, previously scheduled for August 26, 2024. The company stated that a new meeting date will be set and communicated in the future.
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.27% to 38,867.91 while the NASDAQ fell 0.50% to 15,954.75. The S&P 500 also fell, dropping, 0.18% to 5,068.92. Check This Out: Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling  Leading and Lag...
Penny stocks to buy under $1: A Beginner's Guide The post Trading Penny Stocks Under $1: Strategies for Success & 7 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.